Stable graft function after reduction of calcineurin inhibitor dosage in paediatric kidney transplant patients

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2930-2937

  Plank, Christian ^a   Amann, Kerstin ^a   Nüsken, Kai Dietrich ^b   Dittrich, Katalin ^a   Rascher, Wolfgang ^a   Sauerstein, Katja ^a   Stuppy, Anja ^a   Klare, Bernd ^c   Dötsch, Jörg ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Kinderklinik Schwabing   (Germany)

Author keywords

Calcineurin inhibitor toxicity; Ciclosporin; Paediatric renal transplantation; Tacrolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; LIPID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GASTROENTERITIS; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; KIDNEY FAILURE; KIDNEY FUNCTION TEST; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; NEPHROTOXICITY; PEDIATRIC SURGERY; PRIORITY JOURNAL;

EID: 33749602065     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl279     Document Type: Article

References (27)

1. Elshihabi I, Chavers B, Donaldson L, Emmett L, Tejani A. Continuing improvement in cadaver donor graft survival in North American children: the 1998 annual report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2000; 4: 235-246
2. McDonald R, Donaldson L, Emmett L, Tejani A. A decade of living donor transplantation in North American children: The 1998 annual report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2000; 4: 221-234
3. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy in renal transplantation. Transplant Proc 1996; 28: 2100-2103
4. Monaco AP, Burke JF, Jr, Ferguson RM et al. Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 1999; 33: 150-160
5. Pilmore HL, Dittmer ID. Calcineurin inhibitor nephrotoxicity: Reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant 2002; 16: 191-195
6. Abramowicz D, Manas D, Lao M et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation 2002; 74: 1725-1734
7. Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mast BJ, Ijzermans JN, Weimar W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143-148
8. Wong W, Tolkoff-Rubin N, Delmonico FL et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clin Transplant 2004; 18: 341-348
9. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573
10. Weir MR, Blahut S, Drachenburg C et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24: 379-386
11. Soergel M, Kirschstein M, Busch C et al. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: A multicenter trial including 1141 subjects. J Pediatr 1997; 130: 178-184
12. Schwartz GJ, Haycock GB, Edelmann CM, Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259-263
13. David-Neto E, Araujo LP, Feres Alves C et al. A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation. Pediatr Transplant 2002; 6: 313-318
14. de Man SA, Andre JL, Bachmann H et al. Blood pressure in childhood: pooled findings in six European studies. J Hypertens 1991; 9: 109-114
15. David-Neto E, Araujo LM, Lemos FC et al. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 2001; 5: 302-309
16. Filler G, Gellermann J, Zimmering M, Mai I. Effect of adding mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. Transpl Int 2000; 13: 201-206
17. Henne T, Latta K, Strehlau J, Pape L, Ehrich JH, Offner G. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003; 76: 1326-1330
18. Gonzalez Molina M, Seron D, Garcia del Moral R et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77: 215-220
19. Myers BD, Sibley R, Newton L et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590-600
20. Rice JE, Shipp AT, Carlin JB, Vidmar SI, Weintraub RG. Late reduction in cyclosporine dosage does not improve renal function in pediatric heart transplant recipients. J Heart Lung Transplant 2002; 21: 1109-1112
21. Mourad G, Vela C, Ribstein J, Mimran A. Longterm improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998; 65: 661-667
22. Quarto Di Palo F, Castagnone D, Rivolta R et al. Cyclosporine renal cortical vasoconstriction measured by colour Doppler imaging in kidney transplantation. Transpl Int 1992; 5: 21-22
23. Pascual M, Curtis J, Delmonico FL et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75: 1501-1505
24. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-1785
25. Ruiz JC, Campistol JM, Mota A et al. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplant Proc 2003; 35: 1669-1670
26. Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75: 772-780
27. Hoyer PF, Ettenger R, Kovarik JM et al. Everolimus in pediatric de nova renal transplant patients. Transplantation 2003; 75: 2082-2085